{"id":882,"date":"2020-08-26T09:32:18","date_gmt":"2020-08-26T09:32:18","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/elitechgroup-and-r-biopharm-announce-a-worldwide-agreement\/"},"modified":"2021-01-08T11:08:45","modified_gmt":"2021-01-08T11:08:45","slug":"elitechgroup-and-r-biopharm-announce-a-worldwide-agreement","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/elitechgroup-and-r-biopharm-announce-a-worldwide-agreement\/","title":{"rendered":"ELITechGroup and R-Biopharm announce a worldwide agreement"},"content":{"rendered":"<p>ELITechGroup, a leading company in sample-to-result molecular diagnostics, and R-Biopharm, a globally active life science company, have announced a worldwide agreement to strengthen their positions in molecular infectious disease testing. Under this agreement, R-Biopharm and ELITechGroup will cooperate in the development, production and marketing of Real-Time PCR reagents. <br \/>\u201cWe are very pleased to have won R-Biopharm as a partner to expand our molecular diagnostics portfolio.\u201d said Christoph Gauer, CEO of ELITechGroup. \u201cThis collaboration will contribute to complete the menu of our sample-to-result system ELITe InGenius<sup>\u00ae<\/sup>. We will increase the overall number of CE-IVD assays from currently 23 to 33 by the end of 2018 making ELITe InGenius\u00ae the system with the broadest CE-IVD menu on the market.\u201d<br \/>\u201cCollaborating with ELITechGroup will leverage and strengthen the position of R-Biopharm in the field of Molecular Diagnostics, stated Ralf Dreher, CEO of R-Biopharm. As Molecular Diagnostics is one key pillar within the cross divisional strategy in the R-Biopharm Group, we are confident that this partnership will contribute significantly towards the overall success of the company.\u201d<br \/>\n<link http:\/\/www.elitechgroup.com _blank external-link-new-window \"Opens internal link in current window\">www.elitechgroup.com<\/link><link http:\/\/www.r-biopharm.de _blank external-link-new-window \"Opens internal link in current window\">www.r-biopharm.de<\/link>\n","protected":false},"excerpt":{"rendered":"<p>ELITechGroup, a leading company in sample-to-result molecular diagnostics, and R-Biopharm, a globally active life science company, have announced a worldwide agreement to strengthen their positions in molecular infectious disease testing. Under this agreement, R-Biopharm and ELITechGroup will cooperate in the development, production and marketing of Real-Time PCR reagents. \u201cWe are very pleased to have won [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/882"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=882"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/882\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}